EA201590747A1 - Способы лечения с использованием аденовируса - Google Patents

Способы лечения с использованием аденовируса

Info

Publication number
EA201590747A1
EA201590747A1 EA201590747A EA201590747A EA201590747A1 EA 201590747 A1 EA201590747 A1 EA 201590747A1 EA 201590747 A EA201590747 A EA 201590747A EA 201590747 A EA201590747 A EA 201590747A EA 201590747 A1 EA201590747 A1 EA 201590747A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reducing
adenovirus
methods
tumor
treatment
Prior art date
Application number
EA201590747A
Other languages
English (en)
Other versions
EA034163B1 (ru
Inventor
Эйал Брейтбарт
Андреа Леубитц
Эрез Фейге
Ричард Пенсон
Original Assignee
Васкьюлар Байодженикс Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Васкьюлар Байодженикс Лтд. filed Critical Васкьюлар Байодженикс Лтд.
Publication of EA201590747A1 publication Critical patent/EA201590747A1/ru
Publication of EA034163B1 publication Critical patent/EA034163B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение предлагает способ снижения или уменьшения размера опухоли, или устранения опухоли, или ингибирования, уменьшения или снижения неоваскуляризации или ангиогенеза в опухоли у пациента путем введения аденовируссодержащей нуклеотидной конструкции, которая содержит Fas-химерный ген, функционально связанный с промотором, специфичным для эндотелиальных клеток. Изобретение также предлагает гомогенную популяцию аденовируса, содержащего Fas-химерный ген, функционально связанный с промотором, специфичным для эндотелиальных клеток, и способы ее применения.
EA201590747A 2012-10-17 2013-10-17 Конструкция нуклеиновой кислоты, содержащая промотор, специфичный для эндотелиальных клеток, и их противоопухолевое применение EA034163B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715206P 2012-10-17 2012-10-17
US201361785287P 2013-03-14 2013-03-14
PCT/IB2013/003015 WO2014060848A2 (en) 2012-10-17 2013-10-17 Treatment methods using adenovirus

Publications (2)

Publication Number Publication Date
EA201590747A1 true EA201590747A1 (ru) 2015-10-30
EA034163B1 EA034163B1 (ru) 2020-01-13

Family

ID=50488836

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590747A EA034163B1 (ru) 2012-10-17 2013-10-17 Конструкция нуклеиновой кислоты, содержащая промотор, специфичный для эндотелиальных клеток, и их противоопухолевое применение

Country Status (26)

Country Link
US (4) US9200056B2 (ru)
EP (2) EP3441089B1 (ru)
JP (2) JP6336459B2 (ru)
KR (2) KR101989171B1 (ru)
CN (2) CN107096041A (ru)
AU (3) AU2013333571B2 (ru)
BR (1) BR112015008612A2 (ru)
CA (1) CA2888193A1 (ru)
CY (1) CY1121185T1 (ru)
DK (1) DK2908865T3 (ru)
EA (1) EA034163B1 (ru)
ES (1) ES2703913T3 (ru)
HK (1) HK1208625A1 (ru)
HR (1) HRP20182125T1 (ru)
HU (1) HUE042262T2 (ru)
IL (2) IL238313B (ru)
LT (1) LT2908865T (ru)
MX (2) MX366163B (ru)
NZ (1) NZ707336A (ru)
PL (1) PL2908865T3 (ru)
PT (1) PT2908865T (ru)
RS (1) RS58122B1 (ru)
SG (2) SG10201706485WA (ru)
SI (1) SI2908865T1 (ru)
WO (1) WO2014060848A2 (ru)
ZA (1) ZA201502712B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601325A (en) 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
NZ601324A (en) 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
SG10201706485WA (en) 2012-10-17 2017-09-28 Vascular Biogenics Ltd Treatment methods using adenovirus
WO2014118643A2 (en) * 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
UA120611C2 (uk) * 2014-04-04 2020-01-10 Тайхо Фармасьютікал Ко., Лтд. Протипухлинний засіб, який містить таксанову сполуку і підсилювач протипухлинного ефекту
EP3131922B1 (en) * 2014-04-17 2020-05-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides and uses thereof for reducing cd95-mediated cell motility
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE
AU2018206304A1 (en) * 2017-01-06 2019-07-04 Stabilitech Biopharma Ltd Virus
CN111356480A (zh) * 2017-10-20 2020-06-30 脉管生物生长有限公司 用于抗血管生成剂疗法的诊断方法
CN113677351A (zh) * 2018-12-20 2021-11-19 芝加哥大学 与用于癌症疗法的治疗肽相关的方法和组合物
BR112021017780A2 (pt) * 2019-03-13 2022-02-01 Vascular Biogenics Ltd Métodos de terapia anti-tumor
JP2022528425A (ja) * 2019-04-12 2022-06-10 バスキュラー バイオジェニックス リミテッド 抗腫瘍療法
EP4148126A1 (en) * 2020-03-25 2023-03-15 Curigin Co.,Ltd. Immunoevasive anti-tumor adenovirus
WO2022056488A1 (en) * 2020-09-14 2022-03-17 Genprex, Inc. Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
UA70909C2 (ru) 1993-10-25 2004-11-15 Канджи Інк. Рекомбинантный аденовирусный вектор, фармацевтическая композиция и набор для торможения пролиферации опухолевых клеток
ATE314482T1 (de) 1993-10-25 2006-01-15 Canji Inc Rekombinante adenoviren-vektor und verfahren zur verwendung
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
WO2003033514A1 (en) 2001-10-19 2003-04-24 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
CN1294268C (zh) 2001-09-03 2007-01-10 上海三维生物技术有限公司 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体
KR20070044868A (ko) 2005-10-26 2007-05-02 주식회사 바이오인프라 스트렙토라이신 ｏ 단백질을 암호화하는 유전자를 발현하는재조합 아데노바이러스 및 이를 유효성분으로 하는 항암용조성물
WO2008015675A2 (en) 2006-07-31 2008-02-07 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
WO2008074189A1 (fr) 2006-12-20 2008-06-26 Shenzhen Well.D Genetic Engineering Co., Ltd Adénovirus recombinant comprenant un gène khp50 recombinant et son procédé de préparation et ses utilisations
CN101348512B (zh) 2007-07-20 2012-08-15 郑州威瑞生物技术有限公司 一种抗肿瘤的腺病毒制剂
JP4896102B2 (ja) 2008-09-12 2012-03-14 富士フイルム株式会社 レンズ装置
KR101248912B1 (ko) 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
NZ601325A (en) * 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
NZ601324A (en) 2010-01-05 2014-10-31 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
SG182490A1 (en) * 2010-01-12 2012-08-30 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
KR101253276B1 (ko) 2010-07-27 2013-04-10 윤채옥 복합 유전자 치료용 항종양 조성물
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
EP2630186A1 (en) 2010-10-18 2013-08-28 Total Research & Technology Feluy Expandable vinyl aromatic polymers
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
SG10201706485WA (en) * 2012-10-17 2017-09-28 Vascular Biogenics Ltd Treatment methods using adenovirus
WO2014118643A2 (en) * 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent

Also Published As

Publication number Publication date
PL2908865T3 (pl) 2019-08-30
IL275874A (en) 2020-08-31
WO2014060848A2 (en) 2014-04-24
CN107096041A (zh) 2017-08-29
JP2015536318A (ja) 2015-12-21
LT2908865T (lt) 2019-01-10
US20160143968A1 (en) 2016-05-26
AU2017202492B2 (en) 2018-09-06
JP6630397B2 (ja) 2020-01-15
US11311583B2 (en) 2022-04-26
US20190054130A1 (en) 2019-02-21
SI2908865T1 (sl) 2019-02-28
AU2017202492A1 (en) 2017-05-04
IL238313B (en) 2020-07-30
AU2013333571A1 (en) 2015-05-14
HRP20182125T1 (hr) 2019-02-08
MX366163B (es) 2019-07-01
KR102229084B1 (ko) 2021-03-18
ES2703913T3 (es) 2019-03-13
SG10201706485WA (en) 2017-09-28
JP2018140999A (ja) 2018-09-13
IL238313A0 (en) 2015-06-30
NZ707336A (en) 2019-01-25
EP2908865A4 (en) 2016-05-25
US20220331383A1 (en) 2022-10-20
AU2018271398B2 (en) 2020-11-05
CN105025931B (zh) 2017-04-05
SG11201502941VA (en) 2015-05-28
HUE042262T2 (hu) 2019-06-28
JP6336459B2 (ja) 2018-06-06
EP3441089A1 (en) 2019-02-13
MX2015004835A (es) 2015-08-20
EP2908865A2 (en) 2015-08-26
HK1208625A1 (en) 2016-03-11
KR20150068978A (ko) 2015-06-22
EA034163B1 (ru) 2020-01-13
AU2018271398A1 (en) 2018-12-20
CA2888193A1 (en) 2014-04-24
KR101989171B1 (ko) 2019-06-14
AU2013333571B2 (en) 2017-01-19
CN105025931A (zh) 2015-11-04
RS58122B1 (sr) 2019-02-28
US20150044280A1 (en) 2015-02-12
KR20190067279A (ko) 2019-06-14
WO2014060848A3 (en) 2014-11-27
US9200056B2 (en) 2015-12-01
MX2019007057A (es) 2019-08-29
EP3441089B1 (en) 2022-12-14
ZA201502712B (en) 2016-07-27
PT2908865T (pt) 2019-01-11
DK2908865T3 (en) 2019-01-28
CY1121185T1 (el) 2020-05-29
EP2908865B1 (en) 2018-10-03
BR112015008612A2 (pt) 2017-09-26

Similar Documents

Publication Publication Date Title
EA201590747A1 (ru) Способы лечения с использованием аденовируса
EA201490636A1 (ru) Сконструированные с помощью рнк t-клетки для лечения злокачественных новообразований
MX2014010750A (es) Anticuerpos receptores del factor de crecimiento anti-epidermico condicionalmente activos y metodos de uso de los mismos.
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
EA201591198A1 (ru) Антитела к gdf15
TN2014000438A1 (en) Anti-fcrn antibodies
EA201400625A1 (ru) Антитела против pd-l1 и их применение
PH12015502114A1 (en) 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
PH12015500114A1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
TW201611843A (en) Methods of treatment with arginine deiminase
MX360774B (es) Antagonistas de progesterona.
MX2019010098A (es) Antiandrogenos para el tratamiento del cancer de prostata resistente a la castracion no metastasico.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX2015012063A (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf
EA201370196A1 (ru) Антитела, которые связывают фактор роста опухоли-альфа и эпирегулин
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании
AR085105A1 (es) Dosificacion para tratamiento con anticuerpos anti-dominio 7 de tipo de factor de crecimiento epidermico (anti-egfl7)
EA201992441A1 (ru) Способы лечения с использованием аденовируса